The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review

Detalhes bibliográficos
Autor(a) principal: Silva, Danieli Henriques da
Data de Publicação: 2022
Outros Autores: Orozco, Darling Lorena Barros, Coroa , Eduardo, Coêlho, Katiane Alexandre Alves, Baia, Rayane, Valente, Ricardo Leão, Guimarães, Marcia
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/33611
Resumo: Objective: To analyze the scientific literature that deals with the possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review. Methods: This is an integrative literature review, designed as an observational, cross-sectional and qualitative study, data collection was carried out from recent literary and scientific sources, from the year 2020 to the year 2022. Results: Ivermectin is metabolized in the liver, has a half-life four times longer than other drugs, and has great hepatoxic potential. Scientific evidence for its use was based on in vitro research, which shows insufficient results to determine its safety and efficacy. It was found that 05 days of treatment with ivermectin was a safe time to show effective results, with a dose of 0.4 - 0.6mg/kg per day. The interactions of ante - COVID 19 drug candidates with hepatic transporters were identified, these drugs have multiple inhibitory effects on hepatic membrane transporters and can cause toxicity and affect pharmacokinetics. Conclusion: The imprecision of data on the therapeutic use of ivermectiva is evidenced, together with low quality information for clinical guidance, with regard to use, dosage and duration of treatment. As for the possible cytotoxic effect of Ivermectin in patients with covid-19, there were no clinical studies to show such a result, however, its use is contraindicated due to the scarcity of data. Therefore, further randomized clinical trials are needed to determine the level of toxicity of ivermectin in the treatment of SARS-CoV-2.
id UNIFEI_c88a788eb8bc6e79429e5fb091d1141c
oai_identifier_str oai:ojs.pkp.sfu.ca:article/33611
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative reviewLa posible citotoxicidad desarrollada por el uso de ivermectina en pacientes con COVID-19: una revisión integradoraA possível citotoxicidade desenvolvida pelo uso de ivermectina em pacientes com COVID-19: uma revisão integrativa IvermectinCitotoxicidadSARS-CoV-2. IvermectinaCitotoxicidadeSARS-CoV-2. IvermectinCytotoxicitySARS-CoV-2Objective: To analyze the scientific literature that deals with the possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review. Methods: This is an integrative literature review, designed as an observational, cross-sectional and qualitative study, data collection was carried out from recent literary and scientific sources, from the year 2020 to the year 2022. Results: Ivermectin is metabolized in the liver, has a half-life four times longer than other drugs, and has great hepatoxic potential. Scientific evidence for its use was based on in vitro research, which shows insufficient results to determine its safety and efficacy. It was found that 05 days of treatment with ivermectin was a safe time to show effective results, with a dose of 0.4 - 0.6mg/kg per day. The interactions of ante - COVID 19 drug candidates with hepatic transporters were identified, these drugs have multiple inhibitory effects on hepatic membrane transporters and can cause toxicity and affect pharmacokinetics. Conclusion: The imprecision of data on the therapeutic use of ivermectiva is evidenced, together with low quality information for clinical guidance, with regard to use, dosage and duration of treatment. As for the possible cytotoxic effect of Ivermectin in patients with covid-19, there were no clinical studies to show such a result, however, its use is contraindicated due to the scarcity of data. Therefore, further randomized clinical trials are needed to determine the level of toxicity of ivermectin in the treatment of SARS-CoV-2.Objetivo: Analizar la literatura científica que trata sobre la posible citotoxicidad desarrollada por el uso de ivermectina en pacientes con COVID-19: una revisión integradora. Métodos: Se trata de una revisión integrativa de la literatura, diseñada como un estudio observacional, transversal y cualitativo, la recolección de datos se realizó de fuentes literarias y científicas recientes, desde el año 2020 hasta el año 2022. Resultados: La ivermectina se metaboliza en el hígado, tiene una vida media cuatro veces más larga que otras drogas, y tiene un gran potencial hepatotóxico. La evidencia científica para su uso se basó en investigaciones in vitro, que muestran resultados insuficientes para determinar su seguridad y eficacia. Se encontró que 05 días de tratamiento con ivermectina fue un tiempo seguro para mostrar resultados efectivos, con una dosis de 0,4 - 0,6 mg/kg por día. Se identificaron las interacciones de los candidatos a fármacos antI-COVID 19 con los transportadores hepáticos, estos fármacos tienen múltiples efectos inhibitorios sobre los transportadores de la membrana hepática y pueden causar toxicidad y afectar la farmacocinética. Conclusión: Se evidencia la imprecisión de los datos sobre el uso terapéutico de la ivermectiva, junto con información de baja calidad para la orientación clínica, en cuanto a uso, dosis y duración del tratamiento. En cuanto al posible efecto citotóxico de la Ivermectina en pacientes con COVID-19, no existen estudios clínicos que demuestren tal resultado, sin embargo, su uso está contraindicado por la escasez de datos. Por lo tanto, se necesitan más ensayos clínicos aleatorios para determinar el nivel de toxicidad de la ivermectina en el tratamiento del SARS-CoV-2.Objetivo: Analisar a literatura científica que trata da possível citotoxicidade desenvolvida pelo uso de ivermectina em pacientes com COVID-19: uma revisão integrativa. Métodos: Trata-se de uma revisão integrativa de literatura, delineado como um estudo observacional, transversal e qualitativo, realizou-se a coleta de dados a partir de fontes literárias e cientificas recentes, do ano de 2020 até o ano de 2022. Resultados: A metabolização da ivermectina ocorre no fígado, apresenta uma meia vida média de quatro vezes maior do que outros fármacos, grande potencial hepatóxico. As comprovações cientificas para sua utilização, se deram com base em pesquisa in vitro, o que apresenta resultados insuficientes para determinar sua segurança e eficácia. Constatou-se que 05 dias de tratamento com ivermectina, era um tempo seguro para apresentar resultados eficazes, com uma dose de 0,4 - 0,6mg/kg por dia. Identificou-se as interações de candidatos a medicamentos ante – COVID 19 com transportadores hepáticos, esses fármacos, têm múltiplos efeitos inibitórios nos transportadores de membrana hepática e podem causar toxicidade e afetar a farmacocinética. Conclusão: Evidencia-se a imprecisão de dados sobre o uso terapêutico da ivermectiva, juntamente a informações de baixa qualidade para orientação clínica, no que diz respeito ao uso, dosagem e duração do tratamento. Quanto ao possível efeito citotóxico da Ivermectina em pacientes com covid-19, não teve estudos clínicos para evidenciar tal resultado, porém, o seu uso é contraindicado devido à escassez de dados. Portanto, a realização de mais ensaios clínicos randomizados são necessários para determinar o nível de toxicidade da ivermectina no tratamento da SARS-CoV-2.Research, Society and Development2022-09-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3361110.33448/rsd-v11i11.33611Research, Society and Development; Vol. 11 No. 11; e555111133611Research, Society and Development; Vol. 11 Núm. 11; e555111133611Research, Society and Development; v. 11 n. 11; e5551111336112525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/33611/28708Copyright (c) 2022 Danieli Henriques da Silva; Darling Lorena Barros Orozco; Eduardo Coroa ; Katiane Alexandre Alves Coêlho; Rayane Baia; Ricardo Leão Valente; Marcia Guimarãeshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Danieli Henriques da Orozco, Darling Lorena Barros Coroa , Eduardo Coêlho, Katiane Alexandre Alves Baia, Rayane Valente, Ricardo Leão Guimarães, Marcia2022-09-05T13:24:46Zoai:ojs.pkp.sfu.ca:article/33611Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:12.530637Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
La posible citotoxicidad desarrollada por el uso de ivermectina en pacientes con COVID-19: una revisión integradora
A possível citotoxicidade desenvolvida pelo uso de ivermectina em pacientes com COVID-19: uma revisão integrativa
title The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
spellingShingle The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
Silva, Danieli Henriques da
Ivermectin
Citotoxicidad
SARS-CoV-2.
Ivermectina
Citotoxicidade
SARS-CoV-2.
Ivermectin
Cytotoxicity
SARS-CoV-2
title_short The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
title_full The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
title_fullStr The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
title_full_unstemmed The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
title_sort The possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review
author Silva, Danieli Henriques da
author_facet Silva, Danieli Henriques da
Orozco, Darling Lorena Barros
Coroa , Eduardo
Coêlho, Katiane Alexandre Alves
Baia, Rayane
Valente, Ricardo Leão
Guimarães, Marcia
author_role author
author2 Orozco, Darling Lorena Barros
Coroa , Eduardo
Coêlho, Katiane Alexandre Alves
Baia, Rayane
Valente, Ricardo Leão
Guimarães, Marcia
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Danieli Henriques da
Orozco, Darling Lorena Barros
Coroa , Eduardo
Coêlho, Katiane Alexandre Alves
Baia, Rayane
Valente, Ricardo Leão
Guimarães, Marcia
dc.subject.por.fl_str_mv Ivermectin
Citotoxicidad
SARS-CoV-2.
Ivermectina
Citotoxicidade
SARS-CoV-2.
Ivermectin
Cytotoxicity
SARS-CoV-2
topic Ivermectin
Citotoxicidad
SARS-CoV-2.
Ivermectina
Citotoxicidade
SARS-CoV-2.
Ivermectin
Cytotoxicity
SARS-CoV-2
description Objective: To analyze the scientific literature that deals with the possible cytotoxicity developed by the use of ivermectin in patients with COVID-19: an integrative review. Methods: This is an integrative literature review, designed as an observational, cross-sectional and qualitative study, data collection was carried out from recent literary and scientific sources, from the year 2020 to the year 2022. Results: Ivermectin is metabolized in the liver, has a half-life four times longer than other drugs, and has great hepatoxic potential. Scientific evidence for its use was based on in vitro research, which shows insufficient results to determine its safety and efficacy. It was found that 05 days of treatment with ivermectin was a safe time to show effective results, with a dose of 0.4 - 0.6mg/kg per day. The interactions of ante - COVID 19 drug candidates with hepatic transporters were identified, these drugs have multiple inhibitory effects on hepatic membrane transporters and can cause toxicity and affect pharmacokinetics. Conclusion: The imprecision of data on the therapeutic use of ivermectiva is evidenced, together with low quality information for clinical guidance, with regard to use, dosage and duration of treatment. As for the possible cytotoxic effect of Ivermectin in patients with covid-19, there were no clinical studies to show such a result, however, its use is contraindicated due to the scarcity of data. Therefore, further randomized clinical trials are needed to determine the level of toxicity of ivermectin in the treatment of SARS-CoV-2.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-02
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33611
10.33448/rsd-v11i11.33611
url https://rsdjournal.org/index.php/rsd/article/view/33611
identifier_str_mv 10.33448/rsd-v11i11.33611
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33611/28708
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 11; e555111133611
Research, Society and Development; Vol. 11 Núm. 11; e555111133611
Research, Society and Development; v. 11 n. 11; e555111133611
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052797519134720

Registros relacionados